A Phase 4 interventional study of DA-9701 and DA-9701-R in Functional Dyspepsia, sponsored by Dong-A ST Co., Ltd.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Dong-A ST Co., Ltd. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Dyspepsia with a site in Korea, Republic of — 3 open to participants now, 4 under way, none of them phase 3. Dyspepsia · Korea, Republic of.
Among the 28 studies in Dyspepsia with a site in Korea, Republic of, this one is the 7th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2026, is one of 8 in phase 4, and was the 28th registered.
372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.
Browse Dyspepsia studies →3 of the 28 studies in Dyspepsia with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Myungmoon Pharma. Co. Ltd. · Sites in Korea, Republic of
Ages 19+
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 19 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 4 · Phase 4 8
First in 2009; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 89 across 302 interventional studies indexed under Dyspepsia.
Median enrollment 100 across the 26 interventional studies, 206 across the 2 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 28 have an industry lead sponsor. The 10 most frequent:
Dong-A ST Co., Ltd. is the lead sponsor of 122 studies on the registry; 9 are open to participants now.
Dong-A ST Co., Ltd. has 4 studies filed under Dyspepsia — fewer than ten, so there is no comparison to draw.
2 of the studies in Dyspepsia with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07686679Dong-A ST Co., Ltd.A Study to Evaluate the Efficacy and Safety of DA-9701 in Patients With Functional Dyspepsia | 2027-10 |
| NCT07016269Myungmoon Pharma. Co. Ltd.A Study to Evaluate the Efficacy and Safety of CnU Cap. 500 mg in Patients With Biliary Dyspepsia | 2027-11-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in Dyspepsia with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of DA-9701 in patients with functional dyspepsia
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
administered for 4weeks(DA-9701 + DA-9701-R placebo)
Drug: DA-9701 · Drug: DA-9701-R Placebo
administered for 4weeks(DA-9701-R + DA-9701 placebo)
Drug: DA-9701-R · Drug: DA-9701 Placebo
Changes in GIS(Gastrointestinal Symptom Score) total scores
Time frame: Change from baseline at 4 weeks
Changes in GIS(Gastrointestinal Symptom Score) total scores
Time frame: Change from baseline at 2 weeks
Changes in GIS(Gastrointestinal Symptom Score) scores by symptoms
Time frame: Change from baseline at 2 weeks and 4 weeks
Changes in NDI-K QoL(Nepean Dyspepsia Index-Korean version Quality of Life) domain scores and total scores
Time frame: Change from baseline at 4 weeks
Subject's global assessment
Time frame: at week 4
Investigator's global assessment
Time frame: at week 4
Plan to share: Yes
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Oct 2027, 14 months after the start.
Of 31 phase 4 interventional studies under Dyspepsia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 14 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: DA-9701